Abstract: Techniques for providing a QA run cycle and report generation system are provided. In one technique, a user interface (UI) tool retrieves first software testing result data that was generated based on a first type of software test of a software build. The UI tool also retrieves second software testing result data that was generated based on a second type of software test of the software build. In response to receiving first input that selects the first software testing result data, the UI tool updates a UI to present first data that is based on a portion of the first software testing result data. In response to receiving the second input that selects the second software testing result data, the UI tool updates the UI to present second data that is based on a portion of the second software testing result data.

Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

Abstract: Compounds having activity as inhibitors of ENPP1, CdnP, or both are provided herein. Some embodiments provide compounds having one of the following Structures (I) or (II): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7a, R7b, R7b, R7c, R25, R26, R27a, R27b, R27c, L1, L5, L6, G1, G2, G3 and G6 are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for processing inputs using a neural network system that includes one or more pre-normalized layers or one or more regularization normalization layers.

Abstract: Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Abstract: The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

Abstract: A method for operating devices by an electronic device in an Internet of Things (IoT) environment is provided. The method includes monitoring a movement of at least one object from a first location to a second location, identifying a relative position of the at least one object in the second location with respect to at least one entity, predicting an initiation of at least one activity by the at least one entity, based on the determined relative position of the at least one object with respect to the at least one entity, and modifying an operational state of at least one device associated with the predicted at least one activity.

Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.

Abstract: Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

Abstract: The subject matter described herein is directed to methods of treating growth hormone related disorders by administering a long-acting recombinant human growth hormone. In another embodiment, a long-acting recombinant human growth hormone is administered in a composition or the combination is administered separately to treat growth deficiency in a subject previously treated with a once daily rhGH therapy.

Abstract: Methods of treating a stress-related disease or disorder such as PTSD, decreasing side effects of 3,4-methylenedioxy-methamphetamine (MDMA), inducing neurite outgrowth, inducing structural neuroplasticity, or increasing brain-derived neurotrophic factor (BDNF) levels, comprising administering to a subject effective amounts of a composition comprising R(?)-3,4-methylenedioxymethamphetamine (R(?)-MDMA) are disclosed. Also disclosed are pharmaceutical compositions comprising R(?)-MDMA and a pharmaceutically acceptable carrier.

Abstract: Methods and systems for enhanced mobility for voice calls in a new radio band are disclosed. According to an implementation, data services and/or multimedia services may be provided to a user equipment (UE) through a 5G new radio (NR) in a standalone (SA) mode. During the ongoing data service, the UE may receive a voice call in the current NR band. If the current NR band does not support the voice call, the UE may search and acquire a new NR band capable of providing the voice call. The UE may further set the new NR band as the serving cell and transfer the current data radio bearers (DRBs) assigned for the ongoing data service to the new NR band. While the UE receives new DRBs assigned for the voice call, the UE continues the data service and the voice call in the new NR band.

Abstract: Connection configuration for Fourth Generation (4G) and Fifth Generation (5G) converged deployment may be provided. A User Equipment (UE) Usage Type (UUT) mapping may be stored, wherein the UUT mapping includes an Attribute Value Pair (AVP) for one or more UUTs. A connection to a 5G network from a 4G network may be received from a UE, wherein the connection comprises subscription information that includes a UUT the UE is subscribed to. In response to receiving the UUT, a subscriber profile for the UE in a converged packet core may be determined using the UUT mapping, and the configuration of the connection for the UE may be established based on the determined subscriber profile.

Abstract: Particular embodiments described herein provide for an electronic device that can be configured to include a fan where the fan blades are decoupled from the center shaft. The fan can include a center shaft, a motor coil support, motor coils coupled to the motor coil support, a rotator coupled to the center shaft, and fan blades coupled to the rotator, where rotation of the fan blades is decoupled from the center shaft by the rotator. A blade support can be coupled to the rotator, where the blade support couples the fan blades to the rotator and magnets can be coupled to the blade support. In an example, the rotator can include an inner, an outer race, and bearings.

Abstract: Compounds having activity as inhibitors of ENPP1 are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein L, R1, R2a, R2b, R2c, R2d, R2e and n are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: Novel images may be generated using an image generator implemented on a processor. The image generator may receive as input neural features selected from a neural texture atlas. The image generator may also receive as input one or more position guides identifying position information for a plurality of input image pixels. The novel images may be evaluated using an image discriminator to determine a plurality of optimization values by comparing each of the plurality of novel images with a respective one of a corresponding plurality of input images. Each of the novel images may be generated from a respective camera pose relative to an object identical to that of the respective one of the corresponding plurality of input images. The image generator and the neural features may be updated based on the optimization values and stored on a storage device.

Abstract: Techniques for providing a QA run cycle and report generation system are provided. In one technique, a user interface (UI) tool retrieves first software testing result data that was generated based on a first type of software test of a software build. The UI tool also retrieves second software testing result data that was generated based on a second type of software test of the software build. In response to receiving first input that selects the first software testing result data, the UI tool updates a UI to present first data that is based on a portion of the first software testing result data. In response to receiving the second input that selects the second software testing result data, the UI tool updates the UI to present second data that is based on a portion of the second software testing result data.

Abstract: The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.